Home LiteratureArticle Details
PMID: 19794002 Published · ppublish English Comment Editorial

Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future.

Diabetes care ·Vol. 32 ·No. 10 ·2009-10-00 ·Pages 1769-82

Rewers M, Gottlieb P

Abstract

暂无摘要

MeSH Terms
Animals Autoantibodies/immunology Biomedical Research/methods,trends Clinical Trials as Topic Diabetes Mellitus, Type 1/immunology,metabolism,prevention & control,therapy Disease Models, Animal Humans Immunotherapy/methods,trends Mice Mice, Inbred NOD Mice, Knockout
Chemicals
Autoantibodies islet cell antibody
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Rewers Marian
Gottlieb Peter
References (71)
71 references, click to expand
  1. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.
    Diabetes Care. 2006 Mar;29(3):643-9 PMID: 16505520
  2. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes.
    Diabetologia. 2009 Jul;52(7):1363-8 PMID: 19404608
  3. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.
    Diabetes Care. 2009 Jul;32(7):1244-9 PMID: 19366957
  4. Extreme genetic risk for type 1A diabetes.
    Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14074-9 PMID: 16966600
  5. Natural history of beta-cell function in type 1 diabetes.
    Diabetes. 2005 Dec;54 Suppl 2:S32-9 PMID: 16306337
  6. Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort.
    Diabetologia. 2001 Mar;44(3):290-7 PMID: 11317658
  7. Role of insulin resistance in predicting progression to type 1 diabetes.
    Diabetes Care. 2007 Sep;30(9):2314-20 PMID: 17536068
  8. Insulin resistance is a risk factor for progression to type 1 diabetes.
    Diabetologia. 2004 Oct;47(10):1661-7 PMID: 15480539
  9. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
    Diabetes Care. 2005 May;28(5):1068-76 PMID: 15855569
  10. Natural course of remission in IDDM during 1st yr after diagnosis.
    Diabetes Care. 1992 Jan;15(1):66-74 PMID: 1737543
  11. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study.
    Lancet. 2008 May 24;371(9626):1777-82 PMID: 18502302
  12. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
    JAMA. 2007 Apr 11;297(14):1568-76 PMID: 17426276
  13. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
    JAMA. 2009 Apr 15;301(15):1573-9 PMID: 19366777
  14. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.
    Lancet. 1986 Jul 19;2(8499):119-24 PMID: 2873396
  15. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes.
    Diabetes Care. 2003 Apr;26(4):1258-64 PMID: 12663607
  16. Beta-cell mass and type 1 diabetes: going, going, gone?
    Diabetes. 2008 Nov;57(11):2883-8 PMID: 18971435
  17. BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with Type 1 diabetes by delaying exposure to gluten.
    Diabetologia. 2004 Jun;47(6):1130-1 PMID: 15168019
  18. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.
    Scand J Immunol. 2006 Jan;63(1):59-69 PMID: 16398702
  19. Taking a daily vitamin to prevent type 1 diabetes?
    Diabetes. 2009 Jan;58(1):24-5 PMID: 19114727
  20. Islet cell survival determined by morphology. An immunocytochemical study of the islets of Langerhans in juvenile diabetes mellitus.
    Diabetes. 1978;27 Suppl 1:251-61 PMID: 75815
  21. Vitamin-D poisoning: survey of causes in 21 patients with hypercalcaemia.
    Lancet. 1980 May 31;1(8179):1164-5 PMID: 6103986
  22. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.
    Diabetes Metab Res Rev. 2007 May;23(4):276-85 PMID: 17103487
  23. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.
    Lancet. 2004 Mar 20;363(9413):925-31 PMID: 15043959
  24. The Environmental Determinants of Diabetes in the Young (TEDDY) Study.
    Ann N Y Acad Sci. 2008 Dec;1150:1-13 PMID: 19120261
  25. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design.
    Pediatr Diabetes. 2007 Oct;8(5):286-98 PMID: 17850472
  26. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group.
    Diabetes. 1988 Nov;37(11):1574-82 PMID: 2903105
  27. Maternal efforts to prevent type 1 diabetes in at-risk children.
    Diabetes Care. 2005 Apr;28(4):916-21 PMID: 15793195
  28. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.
    Diabetes. 2004 Jan;53(1):250-64 PMID: 14693724
  29. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR).
    Pediatr Diabetes. 2007 Jun;8(3):117-37 PMID: 17550422
  30. Timing of initial cereal exposure in infancy and risk of islet autoimmunity.
    JAMA. 2003 Oct 1;290(13):1713-20 PMID: 14519705
  31. Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside.
    Diabetes Care. 2009 Oct;32(10):1753-68 PMID: 19794001
  32. Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data.
    Pediatr Diabetes. 2008 Jun;9(3 Pt 2):14-22 PMID: 18221429
  33. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1.
    Diabetes Care. 2007 Jan;30(1):38-42 PMID: 17192330
  34. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes.
    Diabetes. 2003 May;52(5):1059-65 PMID: 12716733
  35. Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives.
    Diabetologia. 2006 Dec;49(12):2969-76 PMID: 17019596
  36. Mortality trends in type 1 diabetes. The Allegheny County (Pennsylvania) Registry 1965-1999.
    Diabetes Care. 2001 May;24(5):823-7 PMID: 11347737
  37. Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk.
    Ann N Y Acad Sci. 2006 Oct;1079:310-2 PMID: 17130571
  38. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers.
    Diabetes. 1997 Nov;46(11):1701-10 PMID: 9356015
  39. A comprehensive review of interventions in the NOD mouse and implications for translation.
    Immunity. 2005 Aug;23(2):115-26 PMID: 16111631
  40. GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination.
    Diabet Med. 2007 May;24(5):521-6 PMID: 17367313
  41. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin.
    Diabetes. 1990 Oct;39(10):1264-72 PMID: 2210078
  42. Vitamin D signaling in immune-mediated disorders: Evolving insights and therapeutic opportunities.
    Mol Aspects Med. 2008 Dec;29(6):376-87 PMID: 18621414
  43. Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.
    Clin Exp Immunol. 2007 Apr;148(1):17-31 PMID: 17349010
  44. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
    N Engl J Med. 2008 Oct 30;359(18):1909-20 PMID: 18843118
  45. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
    Diabetes. 2005 Jun;54(6):1763-9 PMID: 15919798
  46. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
    Diabetes Care. 2003 Mar;26(3):832-6 PMID: 12610045
  47. Effects of insulin in relatives of patients with type 1 diabetes mellitus.
    N Engl J Med. 2002 May 30;346(22):1685-91 PMID: 12037147
  48. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study.
    Diabetes Metab Res Rev. 2007 May;23(4):286-91 PMID: 17124721
  49. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus.
    Diabetes Res. 1985 Nov;2(6):271-6 PMID: 3878262
  50. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group.
    Diabetes Care. 2000 Oct;23(10):1516-26 PMID: 11023146
  51. Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth.
    Diabetes Care. 2007 Mar;30(3):503-9 PMID: 17327312
  52. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.
    Rev Diabet Stud. 2004 Summer;1(2):80-8 PMID: 17491669
  53. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience.
    Diabetes. 2006 May;55(5):1463-9 PMID: 16644706
  54. Complete long-term recovery of beta-cell function in autoimmune type 1 diabetes after insulin treatment.
    Diabetes Care. 2004 May;27(5):1207-8 PMID: 15111548
  55. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes.
    Diabetes Care. 2009 Jul;32(7):1250-5 PMID: 19564474
  56. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
    N Engl J Med. 2002 May 30;346(22):1692-8 PMID: 12037148
  57. Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).
    Pediatr Diabetes. 2006 Oct;7(5):247-53 PMID: 17054445
  58. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
    N Engl J Med. 2005 Jun 23;352(25):2598-608 PMID: 15972866
  59. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?
    Diabetologia. 2005 Nov;48(11):2221-8 PMID: 16205882
  60. ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease?
    Diabetes. 2005 May;54(5):1253-63 PMID: 15855308
  61. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.
    Lancet. 2008 Nov 15;372(9651):1746-55 PMID: 18814906
  62. Factors predicting course of beta-cell function in IDDM.
    Diabetes Care. 1992 Aug;15(8):997-1001 PMID: 1505333
  63. Do non-HLA genes influence development of persistent islet autoimmunity and type 1 diabetes in children with high-risk HLA-DR,DQ genotypes?
    Diabetes. 2009 Apr;58(4):1028-33 PMID: 19188433
  64. Secular trends in incidence of childhood IDDM in 10 countries. Diabetes Epidemiology Research International Group.
    Diabetes. 1990 Jul;39(7):858-64 PMID: 2354748
  65. Evidence of an accelerated B-cell destruction in HLA-Dw3/Dw4 heterozygous children with type 1 (insulin-dependent) diabetes.
    Diabetologia. 1986 Jun;29(6):347-51 PMID: 3527834
  66. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.
    Clin Exp Immunol. 2009 Feb;155(2):156-65 PMID: 19040615
  67. Autologous hematopoietic stem cell transplantation for type 1 diabetes.
    Ann N Y Acad Sci. 2008 Dec;1150:220-9 PMID: 19120300
  68. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up.
    Diabetes Care. 2004 Jun;27(6):1399-404 PMID: 15161795
  69. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.
    Diabetes Care. 2009 Nov;32(11):2036-40 PMID: 19690081
  70. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes.
    JAMA. 2007 Sep 26;298(12):1420-8 PMID: 17895458
  71. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
    Lancet. 2001 Nov 24;358(9295):1749-53 PMID: 11734230
Article Info
Journal
Diabetes care
Abbr.
Diabetes Care
ISSN
1935-5548
DOI
10.2337/dc09-0374
Published
2009-10-00
Pages
1769-82
Language
English
Region
United States
NLM ID
7805975
PMCID
PMC2752911
Subset
IM
Corrections
CommentOn
PMID: 19794001
External Links
PubMed source DOI: 10.2337/dc09-0374 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2